Ligand Pharma (LGND) PT Raised to $153 at RBC Capital Following a 'Strong Quarter'
Tweet Send to a Friend
RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $153.00 (from $143.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
